A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

Background To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus. Methods Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily or...

詳細記述

保存先:
書誌詳細
主要な著者: Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
フォーマット: Artigo
言語:Inglês
出版事項: Springer US 2013
主題:
Phase I Studies
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771370/
https://ncbi.nlm.nih.gov/pubmed/23860641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0001-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料